Skip to main content

NewCures

Target Advancement Program FY22 is now open

Learn More

Home

NewCures is a biomedical accelerator that focuses on the development of potential therapeutics from Northwestern University laboratories. Its mission is to strengthen Northwestern’s therapeutic pipeline and to expedite the translational process of early-stage research discoveries into next generation therapeutics to ultimately benefit patients.

Testimonials

NewCures offers resources at a critical phase where innovations would otherwise languish

NewCures offers resources at a critical phase where innovations would otherwise languish

Over the last year and a half under NewCures’ support we have been able to obtain remarkable results indicating that this molecule is on track for clinical trials. Without NewCures, this molecule would not have seen the next step. … I am a true believer in this model for drug translation in academia. It is the best route to move potential drugs toward the clinic…” – Richard Silverman | Weinberg

NewCures defines translational/commercialization trajectories

“NewCures initiated and fostered our relationship with [X] pharmaceuticals that goes beyond the production of drug material components. This work not only permitted us a path to manufacturing at scale, but has provided us with a “one-stop shop,” so to speak, for other key aspects of clinical drug development. … In short, NewCures support has enabled us to take substantive steps to reduce the risk associated with translating our therapy to the clinic.” – C. Shad Thaxton | Feinberg

NewCures defines translational/commercialization trajectories
NewCures supports formulation of strategic, project-specific development plans

NewCures supports formulation of strategic, project-specific development plans

“It has been a fantastically rewarding experience to see our early stage new therapeutic be supported in this manner, … NewCure’s initial report provides an in-depth tech/market assessment and IND GAP analysis of the project. This report has been an invaluable tool, guiding the project on the path to IND.” – Nathan Gianneschi | Weinberg